Clinical Trial Update: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial compares DVRd followed by cilta-cetagene autoleucel versus DVRd followed by autologous stem cell transplant in newly diagnosed multiple myeloma;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Ciltacabtagene autoleucel (Carvykti) (cilta-cetagene autoleucel)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Stichting European Myeloma Network | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING